Jury orders Olympus to pay hospital $6.6 million but rejects claims scopes are unsafe

Hospital must pay $1 million to deceased patient’s family


A jury ordered Olympus Corp. to pay a Seattle hospital $6.6 million in damages tied to a deadly superbug outbreak, and told the hospital to pay $1 million to a deceased patient’s family, according to an article on the Los Angeles Times website.

But the jurors rejected claims that the company’s flagship medical scope was unsafe as designed.

The case was filed by Theresa Bigler, 61, and her four children in connection with the August 2013 death of Richard Bigler, a pancreatic cancer patient who contracted an infection linked to a contaminated Olympus TJF-Q180V duodenoscope. 

Virginia Mason Medical Center later joined the suit against Olympus, but the jury found it shared some blame in the case.

Read the article.

 



July 31, 2017


Topic Area: Infection Control


Recent Posts

Contaminants Under Foot: A Closer Look at Patient Room Floors

So-called dust bunnies on hospital room floors contain dust particles that turn out to be the major source of the bacteria humans breathe.


Power Outages Largely Driven by Extreme Weather Events

Almost half of power outages in the United States were caused by extreme weather events.


Nemours Children's Health Opens New Moseley Foundation Institute Hospital


Code Compliance Isn't Enough for Healthcare Resilience

Intensifying climate risks are pushing hospitals to think beyond code requirements and toward long-term resilience.


Ribbon Cutting Marks First Phase Completion for New Montefiore Einstein Facility

The second phase is expected to be completed in the second half of 2027.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.